Zurück zu den Rankings

BGM Group Ltd. (BGM)

Überbewertet
HealthcareDrug Manufacturers - Specialty & GenericChina

Fundamental

32

Kurs

$7.64

Marktkapitalisierung

$100M

Teil 1 · Was das Unternehmen wert ist

Übersicht

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users

Jinhe Biotechnology Co., Ltd. (金河生物科技股份有限公司)002688.SZ

Both are Chinese producers of tetracycline-class antibiotic active ingredients and premixes sold to the same livestock, poultry and feed customers at home and for export.

Ningxia Tairui Pharmaceutical Co., Ltd. (宁夏泰瑞制药股份有限公司)Not tracked

A non-listed Chinese maker of non-sterile veterinary antibiotic active ingredients and feed additives, selling into the same animal-health raw-material market as BGM's oxytetracycline business.

Wuhan Hvsen Biotechnology Co., Ltd. (武汉回盛生物科技股份有限公司)300871.SZ

Makes veterinary antibiotic active ingredients and the finished animal medicines built on them, competing for the large Chinese pig, poultry and aquaculture producers that also buy BGM's products.

China Animal Husbandry Industry Co., Ltd. (中牧实业股份有限公司)600195.SS

A long-established state-backed supplier of veterinary drugs and veterinary active ingredients to Chinese farms, overlapping with BGM on the animal-medicine side of its pharmaceutical segment.

Bilanz & Liquidität

Umsatz

$39M

Letzte 12 Monate bis zum zuletzt gemeldeten Quartal — Schätzung aus Kennzahlen je Aktie

Nettogewinn

$-25M

Letzte 12 Monate bis zum zuletzt gemeldeten Quartal — Schätzung aus Kennzahlen je Aktie

Freier Cashflow

$-5M

Gesamtes Eigenkapital

$391M

Gesamtverbindlichkeiten

$42M

Current Ratio

1.24

Zinsdeckungsgrad

-

Schulden/EBITDA

-

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

Allgemeiner FallÜberbewertet

Innerer Wert

$0.49

Aktueller Kurs

$7.64

Sicherheitsmarge

-1459.5%

Innerer-Wert-Spanne

$0.47 - $0.52

Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.

Bewertungsmethoden

Kursziel der Analysten:Nicht genügend Daten zur Berechnung
Diskontierter Cashflow (DCF):$0.49
Gewinnmultiplikator (P/E):Nicht genügend Daten zur Berechnung
Graham-Wachstumsformel:Nicht genügend Daten zur Berechnung
Ertragskraftwert (EPV):Nicht genügend Daten zur Berechnung
Gerechtfertigtes P/B:Nicht genügend Daten zur Berechnung
Dividendendiskontierung (Gordon):Nicht genügend Daten zur Berechnung
P/FFO, Funds from Operations:Nicht genügend Daten zur Berechnung
Gewinn im Zyklusmittel:Nicht genügend Daten zur Berechnung
Umsatzmultiplikator:$0.77

Bewertungskennzahlen

P/E-Verhältnis

-

ROE

-5.1%

P/B-Verhältnis

0.13

P/FCF

-

Bruttomarge

16.6%

ROIC

-2.5%

Rentabilitäts-Radar

Wertschöpfung (Wettbewerbsvorteil)

ROIC

-2.5%

WACC

15.0%

ROIC − WACC

-17.5 pp

Der ROIC liegt unter den Kapitalkosten: Das Unternehmen vernichtet für jeden investierten Dollar Wert.

Fundamentalanalyse-Kriterien

Bestanden (4)

  • P/B Ratio 0.13
  • Debt/Equity ratio
  • Current Ratio
  • DCF valuation (Undervalued)

Nicht bestanden (11)

  • EPS shows upward trend
  • Price CAGR -54.62%
  • ROIC -2.5%
  • Gross Margin 16.6%
  • Operating Margin -33.2%
  • Positive Free Cash Flow
  • ROE -7.0%
  • Revenue Growth 5Y -5.4%
  • Share Dilution 1435.7%
  • Net Margin Trend -52.6% vs -5.7%
  • Piotroski F-Score 3/9

Nicht verfügbar (12)

  • P/FCF NaN
  • Dividend Payout NaN%
  • CapEx intensity
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • Analyst Consensus (Finnhub)
  • Earnings Surprise (Finnhub)
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-Score

3/9

Ernsthafte finanzielle Bedenken

score
criteria

Gewinnqualität

-

Niedrige Qualität: Rechnungslegung prüfen

Aktienverwässerung

1435.7%

Neue Aktien werden ausgegeben, Eigentum wird verwässert

Institutionelle Beteiligungen

Für dieses Unternehmen liegen keine institutionellen Meldungen vor.

Unternehmensführung

Führungsteam

NamePositionAlter
Ms. Huandi ZhaoCo-Chief Executive Officer & Director40
Ms. Li HongCo-Chief Executive Officer-
Ms. Yaxuan ZhaiChief Financial Officer30

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Latest News

Recent headlines for BGM, sourced from Markets Gazette.

No recent news for BGM.